Tofacitinib tied to reduced incidence of ILD among Rheumatoid arthritis patients
An Original Investigation in Rheumatology published in JAMA Network Open has found a reduced risk of developing interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients treated with tofacitinib. The risk was reduced by 69%, according to them.
Matthew C. Baker said that future prospective studies with tofacitinib to prevent RA-ILD should be considered.
Insufficient data and research are available on the risk of usage of biologic and targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) on developing interstitial lung disease (ILD) in RA patients.
Considering this background, researchers determined the risk of developing ILD in patients with RA undergoing treatment with different b/tsDMARDs in their respective cohort studies. They calculated Crude incidence rates (IRs) for developing ILD and compared ILD risk in adults with RA, one year or more of continuous enrollment, treatment with a b/tsDMARD of interest, and without preexisting ILD.
They used data from Optum Clinformatics Data Mart (December 2003-December 2019). The exposures in the study were the new administration of adalimumab, abatacept, rituximab, tocilizumab, and tofacitinib.
The results of the research study are:
- Twenty-eight thousand five hundred fifty-nine patients with RA mean age of 55.6 years were included.
- The number of patients treated with adalimumab, abatacept, rituximab, tocilizumab, and tofacitinib were 22 158, 13 326, 5676, 5444, 2548 patients and 1565, respectively.
- Crude IRs per 1000 person-years for ILD for adalimumab, abatacept, rituximab, tocilizumab, and tofacitinib were 3.43, 4.46, 6.15, 5.05, and 1.47, respectively.
- Patients treated with tofacitinib had a lower risk of ILD with aHR of 0.31.4
- Patients treated with tofacitinib had a 68% reduced risk of ILD than adalimumab with aHR 0.32.
- The risk was reduced by 69% of ILD in patients treated with tofacitinib than those treated with adalimumab.
Concluding further, they said among RA patients, those treated with tofacitinib had the lowest incidence of ILD. More research is required to understand how tofacitinib prevents ILD in patients with RA.
They also mentioned words of caution, saying results should be interpreted with caution due to the relatively small sample size of the tofacitinib group.
Further reading:
Baker MC, Liu Y, Lu R, Lin J, Melehani J, Robinson WH. Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs. JAMA Netw Open. 2023;6(3):e233640. doi:10.1001/jamanetworkopen.2023.3640
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.